Depending on the time of CML diagnosed, different regimens were given; historically with IFNa, and more recently with TKIs, including first-generation TKI imatinib and second-generation TKIs dasatinib and nilotinib (Table 1). This evidence concerns the gene IFNA17 and chronic myelogenous leukemia, BCR-ABL1 positive.